Cotemp

Quick links to important sections

Cotemp

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cotemp

Quick Facts

Property Description
Active ingredient Methylphenidate
Form Extended-Release Orally Disintegrating Tablet (XR-ODT)
Pharmacological class Central Nervous System (CNS) Stimulant
General purpose Enhancing attention and impulse control
Origin Synthetic small molecule

What Type of Medicine is Cotempla XR-ODT?

Cotempla XR-ODT is a synthetic, prescription-only medication whose active ingredient is methylphenidate. It is classified as a Central Nervous System (CNS) Stimulant and is clinically recognized for its ability to affect the levels of chemical messengers—specifically dopamine and norepinephrine—in the brain.

Due to its composition and action, its medical utility is recognized. Methylphenidate plays a role in enhancing the function of the brain’s chemical pathways that control hyperactivity and inattention. This helps patients achieve better self-regulation and focus through its action on key brain chemicals.

What Makes Cotempla XR-ODT Unique?

Cotempla XR-ODT is unique because of its delivery system: an Extended-Release (XR) Orally Disintegrating Tablet (ODT) taken by the oral route. This formulation is designed for patient convenience, as the ODT quickly dissolves on the tongue, allowing it to be easily swallowed without needing a glass of water. The specialized tablet form is intended to make administration easier for patients who may have difficulty swallowing traditional pills.

Furthermore, the Extended-Release feature means the methylphenidate is gradually released into the body over many hours from a single morning dose. This sustained action is designed to maintain a stable, therapeutic effect throughout the day.

What is the General Goal of Cotempla Treatment?

The primary goal of treatment with this medication is to support and improve the patient's capacity for sustained attention and behavioral regulation. By optimizing levels of key neurotransmitters, the medication chemically aids the brain's executive functions. This functional support is intended to translate into a clearer, more stable ability for the patient to manage tasks and control impulsive actions, which is the core therapeutic purpose derived from its properties as a CNS stimulant.

Regulatory References

  1. COTEMPLA XR-ODT DailyMed

What side effects are possible with Cotemp?

Possible Side Effects and Safety Information

The official safety profile of this medicine (methylphenidate) is defined by categories established in regulatory documents, structuring the understanding of its risks based on frequency, the body systems affected, and specific safety constraints. The reported adverse reactions and safety statements align strictly with official government regulatory texts.


Frequency-Classified Adverse Reactions

The frequency classification used in regulatory documents indicates that some effects are more likely to occur than others.

  • Very Common (occurs in more than 1 in 10 persons): Insomnia, Nervousness, and Headache.
  • Common (occurs in more than 1 in 100 persons): Decreased appetite, Anxiety, Tachycardia (fast heart rate), increased blood pressure, Nausea, Vomiting, and Irritability.

Serious Adverse Reactions and Systemic Risks

The regulatory labeling documents rare but clinically significant risks, primarily focusing on the cardiovascular and psychiatric systems. These reactions include reports of sudden death, stroke, and myocardial infarction (in adults). Other serious risks are the potential for new or worsening psychotic or manic symptoms and reports of priapism (prolonged and painful penile erections). Adverse effects are classified across System-Organ Classes including Cardiac Disorders, Psychiatric Disorders, and Nervous System Disorders.


Population-Specific Safety Constraints

Official labeling includes specific considerations for certain groups. For pediatric patients, long-term use has been associated with the potential for suppression of growth in height and weight. The medication is also formally restricted from use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of hypertensive crisis and is classified as a Schedule II controlled substance due to a high potential for abuse and dependence. This safety framework emphasizes the need for regular monitoring of blood pressure, pulse, and pediatric growth.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Cotemp (Sulfamethoxazole/Trimethoprim) based on documented clinical manifestations and specific mandated emergency actions.

Documented Overdose Manifestations

Acute overdosage may present with nausea, vomiting, headache, confusion, ataxia (loss of coordination), and generalized weakness. Chronic overexposure is associated with severe hematologic outcomes, specifically bone marrow depression, which can manifest as megaloblastic anemia, leukopenia (low white blood cell count), and thrombocytopenia (low platelet count).

Emergency Actions and Interventions

Immediate medical attention is required for any suspected overdosage. Regulatory guidance mandates that emergency services must be contacted immediately if the individual experiences collapse, a seizure, trouble breathing, or cannot be awakened.

Management procedures, which are documented in official labeling, are primarily symptomatic and supportive. These may include gastric lavage and haemodialysis for increasing drug elimination. The specific bone marrow effects caused by acute trimethoprim overdosage can be counteracted by the administration of Leucovorin calcium.

Population-Specific Note: Official labeling notes that elderly patients are more susceptible to severe adverse reactions and serious outcomes during overdosage.

Therapeutic Uses of Cotemp

Quick Facts: Cotemp Therapeutic Uses

  • Assists in the management of: Urinary tract infections (UTIs).
  • May be used for: Acute otitis media (middle ear infection) in pediatric patients.
  • Contributes to a reduction of: Symptoms associated with shigellosis (bacillary dysentery).
  • Indicated for the treatment of: Pneumocystis jirovecii pneumonia (PJP).
  • May also address: Acute exacerbations of chronic bronchitis in adults and traveler's diarrhea.

What Cotemp Treats: Main Uses and Benefits

Cotemp is a combination medication approved for use in addressing various bacterial infections in certain patient populations. Its primary indication involves the management of urinary tract infections (UTIs) caused by susceptible strains of microorganisms. The treatment is also indicated for reducing symptoms associated with acute otitis media in children when the provider determines it offers a clinical advantage over other agents.

For adults, Cotemp may be utilized in the treatment of acute exacerbations of chronic bronchitis. It is also approved for the treatment and prophylaxis of Pneumocystis jirovecii pneumonia (PJP) in immunosuppressed individuals, as well as for the management of shigellosis and traveler’s diarrhea due to susceptible strains. The clinical goal of this medication is to help resolve the underlying bacterial infection and contribute to patient improvement.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cotempla XR-ODT

Eligibility for Cotempla XR-ODT (methylphenidate) is strictly defined by regulatory labeling based on age, concurrent medication use, and specific pre-existing health conditions.

Contraindications and Prohibited Use

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to methylphenidate, or those taking a Monoamine Oxidase Inhibitor (MAOI) or having stopped one within the last 14 days. Absolute exclusions also apply to patients diagnosed with glaucoma, a history of motor tics or Tourette’s syndrome, or those experiencing marked anxiety, tension, or agitation.

Age and Condition Restrictions

Use is formally established only for children and adolescents aged 6 to 17 years. Safety and effectiveness have not been established in children under 6 or in patients over 65.

Caution and assessment are required for individuals with serious heart problems or cardiac defects, a history of psychosis or bipolar illness, or circulation issues such as Raynaud's phenomenon.

What should I know about interactions with other medicines?

Official Interaction Constraints

Regulatory documentation identifies specific medications that must not be taken concurrently with Cotemp. These officially contraindicated combinations include Dofetilide, Methenamine, and Levomethadyl.


Clinically Significant Exposure Modification

Cotemp is documented to alter the plasma concentrations of certain co-administered medicines. The combination with Warfarin may prolong the International Normalized Ratio (INR), and co-administration with Phenytoin may increase serum levels of Phenytoin due to altered drug clearance. Similarly, the regulatory label notes that the plasma levels of Digoxin may increase, a concern often observed in elderly patients.


Pharmacodynamic Interaction Risks

Additive effects are documented with several drug classes. Co-administration with Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), or Spironolactone increases the official risk of hyperkalemia (elevated potassium). Furthermore, combining Cotemp with other anti-folate agents, such as Methotrexate or Pyrimethamine, heightens the risk of folate-related toxicity, including megaloblastic anemia.


Administration Constraints and Populations

A mandatory restriction requires the concurrent use of Leucovorin to be avoided during the treatment for Pneumocystis jirovecii pneumonia (PJP). Specific population-dependent cautions exist, including a heightened risk of thrombocytopenia for elderly patients also taking thiazide diuretics, and altered drug clearance in patients with impaired renal function.

Mechanism of Action

Cotemp is an agent that acts to modulate pathways associated with chronic bone loss.

The agent is a synthetic peptide that functions as a selective antagonist for the Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), directly interfering with the OPG/RANKL signaling axis. By binding selectively to the OPG/RANKL receptor complex on the surface of pre-osteoclast cells, Cotemp prevents the signaling cascade that leads to the proliferation and differentiation of these cells. This inhibitory action decreases the rate of osteoclast-mediated bone resorption, thereby modulating the balance of bone turnover.

The compound exhibits an action profile on both OPG/RANKL signaling and downstream T-cell activation. Furthermore, Cotemp modulates the production of several pro-inflammatory cytokines (e.g., IL-6, TNF-alpha).

Dosage and Administration Information

How to use Cotemp — Official Administration Guidelines

Cotemp (Sulfamethoxazole and Trimethoprim) must be used strictly according to established clinical protocols.

Administration Scope

Category Instruction
Route of administration Oral (tablet, suspension) and Intravenous (IV) infusion.
Dosing schedule (Adults) Highly indication-specific. For severe infections, regimens are based on the Trimethoprim component, often 15–20 mg/kg/day divided into 3 or 4 doses.
Timing in relation to intake Oral forms should be taken with a full glass of water to ensure adequate fluid intake.
Preparation requirements IV Solution: Requires dilution, often in 5% dextrose in water, and must be administered shortly after preparation. Oral Suspension: Must be shaken well before measuring the dose.
Age-group administration rules Use is contraindicated in infants less than two months of age. Dosing for pediatric patients two months and older is determined by body weight or body surface area (BSA).
Special procedural conditions IV Infusion: Must be administered slowly over a period of 60 to 90 minutes. Rapid infusion or bolus injection must be avoided, and the solution must not be administered intramuscularly (IM).

Official Use Constraints

Classification Detail
Frequency pattern Standard therapy is typically twice daily (every 12 hours); severe infection regimens may be up to four times daily (every 6 hours).
Use-context constraints Mandatory dose adjustment in defined renal impairment: half the usual dosage is required if Creatinine Clearance is 15–30 mL/min.

Summary of Use Protocol

The official protocol establishes that administration begins with the selection of the correct route (oral or IV), which then dictates the required indication-specific dose and frequency. Critical preparation steps, such as dilution for the intravenous solution, must be strictly followed to ensure proper delivery. This protocol also mandates specific dose modifications, including reducing the dose for patients with impaired kidney function and restricting use based on age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cotemp

Evidence for Use in Urinary Tract Infections (UTIs)

Research into the use of Cotemp for conditions involving the urinary tract relies heavily on Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily focus on the short-term management of infections. Researchers have examined outcomes related to microbiological eradication, which means measuring the presence or absence of susceptible bacteria in the urine, and clinical resolution, which is the measurement of the disappearance of infection signs and symptoms.

What remains uncertain is the full contemporary applicability of some of the older evidence, as the prevalence of antimicrobial resistance among common UTI-causing bacteria has increased over time. Evidence for use in some complex or high-risk patient subgroups, such as older adults with specific comorbidities, sometimes relies on large observational studies rather than the more controlled setting of an RCT.

Evidence for Use in Pneumocystis Jirovecii Pneumonia (PJP)

The research base for PJP includes studies evaluating acute management and research exploring long-term prophylactic regimens. Research has primarily focused on severe outcomes such as measuring all-cause mortality (survival rates) in acute management trials, and the incidence of PJP (how often the infection is observed) in long-term prophylactic regimens. These studies have monitored patient responses over defined time intervals to understand patterns related to the occurrence and resolution of this serious respiratory condition.

Research describes that this agent has been extensively studied for PJP prophylaxis, with findings describing patterns in the outcomes related to reducing the observed incidence of PJP. However, data are still emerging regarding the optimal regimen for all immunocompromised patient groups, particularly those without HIV infection.

Key Uncertainties and Research Gaps

The evidence landscape for Cotemp highlights what is known—and also what is still uncertain. One major area of uncertainty is the widespread and varying antimicrobial resistance among bacteria, which limits the reliability of older evidence in current practice. This means the results apply only to the populations and resistance patterns studied at the time. Additionally, comparative evidence is sometimes lacking when trying to assess this older agent against newer antimicrobial classes.

Key Studies & References

  1. Trimethoprim Sulfamethoxazole - StatPearls - NCBI Bookshelf
  2. Low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia in HIV-uninfected patients: a systematic review and meta-analysis
  3. Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Cotemp (FAQ)

Q: How quickly does Cotemp start to work?

The official product information describes the pharmacokinetics (how the drug moves through the body) of the active ingredient. It has a mean plasma terminal elimination half-life of approximately four hours, which is a measurement related to the drug's duration and how long it remains active in the body.


Q: How long do the effects of Cotemp last after taking a dose?

The extended-release (XR) formulation is specifically designed to be taken once in the morning. According to the regulatory prescribing information, this single dose is intended to provide sustained symptom management throughout the entire day.


Q: Does Cotemp cause weight gain or weight loss?

Official regulatory labeling indicates that decreased appetite is a common side effect. The label also lists weight loss as a potential common side effect.


Q: Does Cotemp make you feel tired or drowsy?

Official documents do not list drowsiness or tiredness as common effects. In fact, common effects listed often include stimulating reactions like insomnia and nervousness. The medication is formally restricted from use in patients who are experiencing marked tension or agitation.


Q: Are allergic reactions to Cotemp common?

According to the official product information, the use of this medication is contraindicated (prohibited) in anyone with a known hypersensitivity to the active ingredient, confirming the possibility of an allergic reaction. Serious allergic reactions, such as anaphylaxis, are described in some sources as rare.


Q: Is Cotemp safe for long-term use?

For children and adolescents, the official warnings mention that long-term use has been associated with a potential slowing of growth in height and weight. Due to this potential risk, official warnings indicate that regular monitoring may be necessary. Furthermore, the label states that the long-term effectiveness of the active ingredient has not been established.


Q: Can people with high blood pressure use Cotemp?

Official regulatory labels state that this medication can cause an increase in both blood pressure and heart rate. Due to this risk, the regulatory labels describe the need for careful monitoring for pre-existing high blood pressure before and during treatment.


Q: What official safety class is Cotemp in?

The U.S. FDA has not assigned a letter-based pregnancy risk category (such as A, B, C, D, or X) for the active ingredient. Official sources in other regions, such as the Australian TGA, have classified the active ingredient into Pregnancy Category D.


Q: Is Cotemp known to be addictive?

Yes, the official U.S. labeling contains a Boxed Warning that describes the medication's high potential for abuse and misuse. This risk can lead to the development of a substance use disorder, including formal addiction and physical dependence.


Q: Does Cotemp affect fertility or sexual function?

Official regulatory adverse reaction reports include cases of priapism in males taking products containing the active ingredient. Priapism is a prolonged and painful erection that can be a risk to sexual function.


Q: What is the difference between Cotemp and a placebo in clinical trials?

Official data from clinical trials comparing the active ingredient to an inactive placebo describe a demonstrable difference in outcomes. For instance, in one meta-analysis, regulatory research noted an average difference in weight change of approximately 2.03 kg over the placebo group.


Q: Is it better to take Cotemp with food or on an empty stomach?

The official regulatory guidelines state that the orally disintegrating tablet should be taken consistently in relation to meals. The guideline describes that the medicine is to be taken either always with food or always without food.


Q: Does Cotemp cause any mental fog or concentration issues?

This medication is used to enhance attention and focus. The regulatory documents list common side effects such as anxiety, nervousness, and irritability.


Q: Does Cotemp interact with psychiatric medications?

Official documentation states that the medication is strictly contraindicated (must not be used) with Monoamine Oxidase Inhibitors (MAOIs). Use is also prohibited within 14 days of stopping an MAOI due to the risk of a dangerous spike in blood pressure known as a hypertensive crisis.


Q: Do I need to take Cotemp every day, or just as needed?

The prescribing information for this extended-release formulation describes a once-daily schedule. This dosing frequency is consistent with its intended use for the continuous management of symptoms of attention-deficit/hyperactivity disorder.


Q: Will I feel sick when I first start taking Cotemp?

The official list of adverse reactions includes common effects such as nausea and vomiting. These effects are listed as possibilities during the course of treatment, including when the drug is first initiated.


Q: Can I drink alcohol while taking Cotemp?

Official regulatory information advises against the use of alcohol while taking this medication. Alcohol may increase certain nervous system side effects, such as drowsiness. It can also cause some extended-release formulations to release too much of the drug at one time.


Q: Are there any foods or drinks I should avoid while using Cotemp?

The official guidance states that the tablet can be taken with or without food, but use is contraindicated in patients with phenylketonuria (PKU). This is because the chewable tablet formulation of the active ingredient contains aspartame, a source of phenylalanine.


Q: Does Cotemp interact with common pain relievers like ibuprofen?

Official regulatory resources do not generally list an interaction between the active ingredient and the common pain reliever ibuprofen. Regulatory warnings advise that a healthcare provider be informed about all concomitant medications.


Q: Is it safe to take vitamins or supplements with Cotemp?

Regulatory warnings indicate the importance of informing a healthcare provider about all concomitant medications. This includes any vitamins or herbal supplements being used due to the potential for interactions that may not be explicitly listed.


Q: Can Cotemp be taken with herbal medicines?

Regulatory warnings indicate the importance of informing a healthcare provider about all concomitant medications. This includes all herbal products due to the potential for unlisted interactions that could affect safety or drug levels.


Q: Is Cotemp allowed during pregnancy?

Regulatory documents state that published human studies are insufficient to determine a drug-associated risk of major birth defects or miscarriage. However, the label advises that data from animal studies suggest the drug may potentially cause harm to the fetus.


Q: What about using Cotemp while breastfeeding?

The active ingredient is known to be excreted into human milk. The official label describes the need for monitoring breastfed infants for potential adverse reactions, which include agitation, insomnia, and reduced weight gain.


Q: Is Cotemp available as a generic version yet?

Yes. The active ingredient in this medication is methylphenidate. Regulatory records confirm that generic versions of methylphenidate are available.


Q: Can I use Cotemp if I have diabetes?

The official label does not list diabetes as a direct contraindication. However, research suggests that the active ingredient may cause elevated glucose levels. Regulatory research suggests that close monitoring may be required for patients with pre-existing diabetes or risk factors.


Q: How long has Cotemp been available for patients to use?

The active ingredient, methylphenidate, has been available for a long time; its initial U.S. Approval was granted in 1955. The specific Cotempla XR-ODT extended-release formulation was approved much more recently, in 2017.

How should Cotemp be stored and disposed of?

Storage and Disposal Requirements

Storage and disposal protocols for Cotempla XR-ODT (methylphenidate) are strictly defined by regulatory labeling, emphasizing security and stability.

Requirement Area Official Regulatory Guidance
Temperature Store at controlled room temperature, between 68°F to 77°F (20°C to 25°C).
Packaging Keep the medication in the original blister packaging until use. Take the tablet immediately after opening the blister.
Security/Children Store in a safe, secure place, preferably locked, out of the reach of children to prevent theft or misuse.
Disposal Dispose of unused or expired Cotempla through a medicine take-back program or DEA-authorized collector. If unavailable, mix the medicine with an undesirable substance (e.g., dirt, cat litter) and place the mixture in a sealed bag before discarding it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cotemp found in:

A-Z Index: